Protein corona-coated immunomagnetic nanoparticles with enhanced isolation of circulating tumor cells. Issue 23 (6th June 2022)

• Record Type: Journal Article
• Authors: Jiang, Xinbang; Zhang, Xiangyun; Guo, Chen; Yu, Yameng; Ma, Boya; Liu, Zhuang; Chai, Yamin; Wang, Lichun; Du, Yunzheng; Wang, Biao; Li, Nan; Dong, Dong; Li, Yueguo; Huang, Xinglu; Ou, Lailiang
• Is Part Of: Nanoscale. Volume 14:Issue 23(2022)
• Page Start: 8474
• Page End: 8483
• Publication Date: 2022-06-06
• Subjects: Nanoscience -- Periodicals; Nanotechnology -- Periodicals; 620.505
• DOI: 10.1039/d2nr01568d
• Languages: English
• ISSNs: 2040-3364

Abstract

Abstract : Schematic illustrations of the preparation of IC-MNs for enhanced isolation of CTCs. Abstract : Immunomagnetic nanoparticles (IMNs) have been widely developed as a detection tool to isolate rare circulating tumor cells (CTCs) from whole blood as a potential method for early cancer diagnosis, metastasis examination, and treatment guidance. However, a spontaneous interaction between nanoparticles and proteins results in the formation of a protein corona that reduces the performance of IMNs when they enter body fluids. To address this issue, the protein corona was precoated onto magnetic nanoparticles (C-MNs), and then their surfaces were conjugated with an immuno-antibody. The adsorption of proteins on C-MNs was decreased 6-fold and non-specific cell binding was reduced 5-fold, compared with magnetic nanoparticles (MNs). Furthermore, the immuno-antibody functionalized C-MNs (IC-MNs) maintained highly specific CTC capture performance when exposed to blood plasma. By using artificial spiked blood samples, IC-MNs exhibited 90.2% CTC isolation efficiency, compared with 60.3% by using IMNs. IC-MNs also successfully captured CTCs with high purity in 24 out of 26 female breast cancer patient blood samples. This work demonstrated that a novel preformed protein corona strategy can provide a useful clinically applicable diagnostic tool.